IMM
Director Trades
| Date | Director | Value |
|---|
Company News
Immutep delivers major breakthrough with 59.6% response rate in lung cancer trial
Late-stage biotechnology specialist Immutep (ASX: IMM) has achieved significant improvement in response rates compared to historical controls in a trial evaluating its first-line non-small cell lung cancer (NSCLC) treatment candidate. The assessment of eftilagimod alpha (efti) with Keytruda and chemotherapy has achieved high response rates in the multi-centre INSIGHT-003 trial, an investigator-initiated study conducted by […]
Immutep delivers strong survival results in efti-Keytruda head and neck cancer immunotherapy trial
Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase IIb trial to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). The study, which evaluated eftilagimod alfa (efti) in combination with anti-PD-1 therapy Keytruda (pembrolizumab) as first-line therapy for […]
Immutep’s efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials
Immutep (ASX: IMM) has presented new data from a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus Keytruda (pembrolizumab) for patients with soft tissue sarcoma (STS). Based on preliminary analysis of 21 patients available for primary endpoint assessment, the trial at Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in […]
Immutep reports strong results from efti-KEYTRUDA combination in carcinoma treatment
Clinical-stage biotechnology company Immutep (ASX: IMM) has released top-line results from a Phase IIb trial evaluating eftilagimod alfa (efti) in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab) as a first-line treatment for recurrent and metastatic head and neck squamous cell carcinoma. The results showed that a combination of both drugs can lead to overall response rates […]
Immutep doses first patient in Phase II/III efti trial to treat metastatic breast cancer
Biotechnology company Immutep (ASX: IMM) has safely dosed the first patient at a European clinical site for its integrated Phase II/III AIPAC-003 trial to treat metastatic breast cancer. AIPAC-003 is evaluating the company’s soluble LAG-3 protein and first-in-class MHC Class II agonist known as eftilagimod alpha (efti) in combination with standard-of-care paclitaxel for the treatment […]
Immutep’s Chinese partner launches phase II clinical trial for patients with metastatic breast cancer
Global biotechnology company Immutep (ASX: IMM) has announced its Chinese partner EOC Pharma will commence a phase II clinical trial to evaluate the efficacy and safety of lead drug eftilagimod alpha in treating metastatic breast cancer. The trial follows encouraging results from an ongoing AIPAC (Active Immunotherapy Paclitaxel) phase IIb study launched earlier this year […]
Immutep announces improved results in two parallel clinical trials into lead drug eftilagimod alpha
Biotechnology company Immutep (ASX: IMM) has unveiled results from two parallel clinical studies into its lead drug eftilagimod alpha, citing “improving results” and “encouraging” early anti-tumour activity signals a variety of cancer indications not typically sensitive to immune checkpoint inhibitor (ICI) therapy. In Immutep’s INSIGHT-004 phase I clinical trial was conducted in Frankfurt, Germany, in […]
Immutep receives US patent for the use of LAG525 antibody in treating various cancers
Biotech company Immutep (ASX: IMM) has been granted a US patent directed to embodiments of LAG525, a humanised form of its IMP701 antibody. The patent is directed to nucleic acid molecules which code for the LAG525 antibody in immunotherapy for solid tumours, blood cancer and breast cancer (in partnership with Novartis AG). It is also […]
Immutep publishes interim results for two ongoing studies, scoops $3.6 million in R&D grant
Biotechnology company Immutep (ASX: IMM) has published results from two ongoing clinical studies, just days after revealing it received €2.1 million (A$3.6 million) in research and development tax incentive payments from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The funds are designated for developing the company’s lead drug eftilagimod alpha and the preclinical development […]
Immutep receives further FDA approval for efti cancer drug
Biotechnology company Immutep (ASX: IMM) has received approval from the US Food and Drug Administration for an investigational new drug (IND) application relating to its lead product candidate eftilagimod alpha for the treatment of metastatic breast cancer. The IND approval allows Immutep to initiate a planned AIPAC-002 phase I clinical study in 24 metastatic breast […]